Repaglinide pharmacokinetics in healthy young adult and elderly subjects

In this open-label, single-center, pharmacokinetic study of repaglinide, 12 healthy volunteers (6 men, 6 women) were enrolled in each of 2 groups (tot al, 24 volunteers). One group consisted of young adult subjects (18 to 40 y ears), and the other group consisted of elderly subjects (greater than or e qual to 65 years). On day 1, after a 10-hour fast, all 24 subjects received a single 2-mg dose of repaglinide. Starting on day 2 and continuing for 7 days, subjects received a 2-mg dose of repaglinide 15 minutes before each o f 3 meals. On day 9, subjects received a single 2-mg dose of repaglinide. P harmacokinetic profiles, including area under the curve, maximum concentrat ion (C-max), time to C-max, and half-life, were determined at completion of the single-dose and multiple-dose regimens (days 1 and 9,respectively). Tr ough repaglinide values were collected on days 2 through 7 to assess steady state. The single-dose and multiple-dose pharmacokinetic variables of seru m repaglinide were not significantly different between young adult and elde rly subjects. Repaglinide was well tolerated in both groups. Hypoglycemic e vents occurred in 5 young adult and 5 elderly subjects. This study demonstr ates that the pharmacokinetics of repaglinide are similar in healthy young adult and elderly subjects.